FAQ

LBH589

Known as: (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, LBH 589, NVP-LBH589 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2018
010203020042018

Related topics

Related topics

1 relation

Broader (1)

panobinostat

Related mentions per year

Related mentions per year

2000-2018
20002005201020152020
LBH589
panobinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells
LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor activity in multiple myeloma and other… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
Despite the significant progress made in colon cancer chemotherapy, advanced disease remains largely incurable and novel… (More)
  • table 1
  • table 1
  • table 2
  • table 2
  • table 3
Is this relevant?
2007
2007
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Activating mutations in the epidermal growth factor receptor (EGFR) selectively activate signal transducers and activators of… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Multiple myeloma represents an incurable disease, for which development of new therapies is required. Here, we report the effect… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
PURPOSE Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
PURPOSE LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In… (More)
  • table 2
  • figure 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Histone deacetylase (HDAC) inhibitors have shown cytotoxicity as single agents in preclinical studies for multiple myeloma (MM… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Present studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, induces acetylation of… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce… (More)
Is this relevant?